Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort-the DIABET-IC study.
Cardiometabolic
Cardiovascular disease
Diabetes mellitus
Heart failure
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
28
05
2024
accepted:
11
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
Type 2 diabetes (T2D) patients have an increased risk of heart failure (HF). There are limited data on the association between HF and T2D in specific healthcare settings. This study sought to analyse the prevalence and incidence of HF in a contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics. We conducted an observational multicentre prospective study (DIABET-IC) that enrolled patients with a T2D diagnosis attending cardiology and endocrinology outpatient clinics in 30 centres in Spain between 2018 and 2019. The prevalence at the start of the study and the incidence of HF after a 3 year follow-up were calculated. HF was defined as the presence of typical symptoms and either: a) LVEF < 40%; or b) LVEF ≥ 40% with elevated natriuretic peptides and echocardiographic abnormalities. A total of 1249 T2D patients were included in the present analysis (67.6 ± 10.1 years, 31.7% female). HF was present in 490 participants at baseline (prevalence 39.2%), 150 (30.6%) of whom had a preserved ejection fraction. The presence of adverse social determinants and chronic conditions such as chronic kidney disease and atherosclerotic cardiovascular disease were more frequent in HF patients. During the study period, there were 58 new diagnoses of HF (incidence 7.6%) among those without baseline HF. The incidence rate was 3.0 per 100 person-years. Independent predictors of incident HF were smoking, left ventricular ejection fraction, NT-ProBNP, history of tachyarrhythmia and treatment with pioglitazone, oral anticoagulants, or diuretics. Despite an average suboptimal glycaemic control, the use of antidiabetic drugs with cardiovascular benefits was low (30.4% for sodium-glucose cotransporter-2 inhibitors and 12.5% for glucagon-like peptide-1 receptor agonists). In this contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics, the prevalence and incidence of HF were high, comorbidities were frequent, and the use of antidiabetic agents with cardiovascular benefit was low. Outpatient care seems to be a unique opportunity for a comprehensive T2D approach that encompasses HF prevention, diagnosis, and treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes (T2D) patients have an increased risk of heart failure (HF). There are limited data on the association between HF and T2D in specific healthcare settings. This study sought to analyse the prevalence and incidence of HF in a contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics.
METHODS
METHODS
We conducted an observational multicentre prospective study (DIABET-IC) that enrolled patients with a T2D diagnosis attending cardiology and endocrinology outpatient clinics in 30 centres in Spain between 2018 and 2019. The prevalence at the start of the study and the incidence of HF after a 3 year follow-up were calculated. HF was defined as the presence of typical symptoms and either: a) LVEF < 40%; or b) LVEF ≥ 40% with elevated natriuretic peptides and echocardiographic abnormalities.
RESULTS
RESULTS
A total of 1249 T2D patients were included in the present analysis (67.6 ± 10.1 years, 31.7% female). HF was present in 490 participants at baseline (prevalence 39.2%), 150 (30.6%) of whom had a preserved ejection fraction. The presence of adverse social determinants and chronic conditions such as chronic kidney disease and atherosclerotic cardiovascular disease were more frequent in HF patients. During the study period, there were 58 new diagnoses of HF (incidence 7.6%) among those without baseline HF. The incidence rate was 3.0 per 100 person-years. Independent predictors of incident HF were smoking, left ventricular ejection fraction, NT-ProBNP, history of tachyarrhythmia and treatment with pioglitazone, oral anticoagulants, or diuretics. Despite an average suboptimal glycaemic control, the use of antidiabetic drugs with cardiovascular benefits was low (30.4% for sodium-glucose cotransporter-2 inhibitors and 12.5% for glucagon-like peptide-1 receptor agonists).
CONCLUSIONS
CONCLUSIONS
In this contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics, the prevalence and incidence of HF were high, comorbidities were frequent, and the use of antidiabetic agents with cardiovascular benefit was low. Outpatient care seems to be a unique opportunity for a comprehensive T2D approach that encompasses HF prevention, diagnosis, and treatment.
Identifiants
pubmed: 39014420
doi: 10.1186/s12933-024-02358-0
pii: 10.1186/s12933-024-02358-0
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Observational Study
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Subventions
Organisme : Instituto de Salud Carlos III
ID : Río Hortega Contract (CM22/00259)
Informations de copyright
© 2024. The Author(s).
Références
Yan T, Zhu S, Yin X, et al. Trends burden inequalities of heart failure globally 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study. J Am Heart Assoc. 2023. https://doi.org/10.1161/JAHA.122.027852 .
doi: 10.1161/JAHA.122.027852
pubmed: 37804191
pmcid: 10757547
Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on Heart Failure in the United States: the medical expenditure panel survey 2009–2018. JACC Heart Fail. 2022;10(8):571–80. https://doi.org/10.1016/j.jchf.2022.05.006 .
doi: 10.1016/j.jchf.2022.05.006
pubmed: 35902161
pmcid: 9680004
Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18(1):1–11. https://doi.org/10.1186/S12872-018-0815-3/TABLES/7 .
doi: 10.1186/S12872-018-0815-3/TABLES/7
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020. https://doi.org/10.21037/amj.2020.03.03 .
doi: 10.21037/amj.2020.03.03
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107. https://doi.org/10.2991/JEGH.K.191028.001 .
doi: 10.2991/JEGH.K.191028.001
pubmed: 32175717
pmcid: 7310804
Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–34. https://doi.org/10.1016/S0140-6736(23)01301-6 .
doi: 10.1016/S0140-6736(23)01301-6
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–67. https://doi.org/10.1016/S0140-6736(22)01429-5 .
doi: 10.1016/S0140-6736(22)01429-5
pubmed: 36041474
Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferović PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022. https://doi.org/10.1186/S12933-022-01575-9 .
doi: 10.1186/S12933-022-01575-9
pubmed: 35927730
pmcid: 9351217
Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol. 2015;7(3):119. https://doi.org/10.4330/WJC.V7.I3.119 .
doi: 10.4330/WJC.V7.I3.119
pubmed: 25810811
pmcid: 4365308
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018. https://doi.org/10.1186/S12933-018-0728-6 .
doi: 10.1186/S12933-018-0728-6
pubmed: 29884191
pmcid: 5994068
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America. J Card Fail. 2019;25(8):584–619. https://doi.org/10.1016/J.CARDFAIL.2019.05.007 .
doi: 10.1016/J.CARDFAIL.2019.05.007
pubmed: 31174952
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. https://doi.org/10.1016/0002-9149(74)90089-7 .
doi: 10.1016/0002-9149(74)90089-7
pubmed: 4835750
Pandey A, Khan MS, Patel KV, Bhatt DL, Verma S. Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11(8):607–24. https://doi.org/10.1016/S2213-8587(23)00128-6 .
doi: 10.1016/S2213-8587(23)00128-6
pubmed: 37385290
Rodríguez-Padial L, Pérez A, Sánchez MA, Barrios V, Orna JAG, Muñiz J. Characteristics of women with type 2 diabetes and heart failure in Spain. The DIABET-IC study Cardiol J. 2024;31(1):103–10. https://doi.org/10.5603/CJ.A2023.0016 .
doi: 10.5603/CJ.A2023.0016
pubmed: 36896635
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. https://doi.org/10.1016/S0140-6736(07)61602-X .
doi: 10.1016/S0140-6736(07)61602-X
Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27. https://doi.org/10.2337/DC18-S002 .
doi: 10.2337/DC18-S002
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200m. https://doi.org/10.1093/EURHEARTJ/EHW128 .
doi: 10.1093/EURHEARTJ/EHW128
pubmed: 27206819
Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501–25. https://doi.org/10.1161/CIRCRESAHA.120.315913 .
doi: 10.1161/CIRCRESAHA.120.315913
pubmed: 32437308
pmcid: 7251974
Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11(10):1390–400. https://doi.org/10.1016/J.JCMG.2018.03.015 .
doi: 10.1016/J.JCMG.2018.03.015
pubmed: 29778859
Somaratne JB, Whalley GA, Poppe KK, et al. Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community. Cardiovasc Diabetol. 2011. https://doi.org/10.1186/1475-2840-10-29 .
doi: 10.1186/1475-2840-10-29
pubmed: 21929744
pmcid: 3182888
Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628–37. https://doi.org/10.1016/S0735-1097(00)00582-9 .
doi: 10.1016/S0735-1097(00)00582-9
pubmed: 10807470
Van Melle JP, Bot M, De Jonge P, De Boer RA, Van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(9):2084–9. https://doi.org/10.2337/DC10-0286 .
doi: 10.2337/DC10-0286
pubmed: 20805280
pmcid: 2928369
Boonman-De Winter LJM, Rutten FH, Cramer MJM, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154–62. https://doi.org/10.1007/S00125-012-2579-0 .
doi: 10.1007/S00125-012-2579-0
pubmed: 22618812
pmcid: 3390708
Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health. 2000;54(3):173–7. https://doi.org/10.1136/JECH.54.3.173 .
doi: 10.1136/JECH.54.3.173
pubmed: 10746110
pmcid: 1731634
Ohlsson A, Eckerdal N, Lindahl B, Hanning M, Westerling R. Non-employment and low educational level as risk factors for inequitable treatment and mortality in heart failure: a population-based cohort study of register data. BMC Public Health. 2021. https://doi.org/10.1186/S12889-021-10919-1 .
doi: 10.1186/S12889-021-10919-1
pubmed: 34078322
pmcid: 8170987
Witte KK, Patel PA, Walker AMN, et al. Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure. Heart. 2018;104(12):993–8. https://doi.org/10.1136/HEARTJNL-2017-312539 .
doi: 10.1136/HEARTJNL-2017-312539
pubmed: 29386325
Lawson CA, Zaccardi F, Squire I, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health. 2019;4(8):e406–20. https://doi.org/10.1016/S2468-2667(19)30108-2 .
doi: 10.1016/S2468-2667(19)30108-2
pubmed: 31376859
pmcid: 6686076
Loosen SH, Roderburg C, Curth O, et al. The spectrum of comorbidities at the initial diagnosis of heart failure a case control study. Sci Rep. 2022. https://doi.org/10.1038/S41598-022-06618-5 .
doi: 10.1038/S41598-022-06618-5
pubmed: 35177698
pmcid: 8854549
Escobar C, Varela L, Palacios B, et al. Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Rev Clin Esp. 2022;222(4):195–204. https://doi.org/10.1016/J.RCENG.2021.04.005 .
doi: 10.1016/J.RCENG.2021.04.005
pubmed: 34511336
Nambi V, Ballantyne CM, Hoogeveen RC, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016;4(10):840–9. https://doi.org/10.1016/S2213-8587(16)30196-6 .
doi: 10.1016/S2213-8587(16)30196-6
pubmed: 27599814
Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(9):989–98. https://doi.org/10.1001/JAMACARDIO.2016.3030 .
doi: 10.1001/JAMACARDIO.2016.3030
pubmed: 27681000
Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891–8. https://doi.org/10.1002/EJHF.3036 .
doi: 10.1002/EJHF.3036
pubmed: 37712339
Obokata M, Reddy YNV, Melenovsky V, Sorimachi H, Jarolim P, Borlaug BA. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. Eur J Heart Fail. 2022;24(2):353–61. https://doi.org/10.1002/EJHF.2377 .
doi: 10.1002/EJHF.2377
pubmed: 34755429
Pharmacologic Approaches to Glycemic Treatment. Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78. https://doi.org/10.2337/DC24-S009 .
doi: 10.2337/DC24-S009
Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020. https://doi.org/10.1161/JAHA.119.014908 .
doi: 10.1161/JAHA.119.014908
pubmed: 31992158
pmcid: 7033896
Baigent C, Emberson JR, Haynes R, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801. https://doi.org/10.1016/S0140-6736(22)02074-8 .
doi: 10.1016/S0140-6736(22)02074-8
Martín E, López-Aguilera J, González-Manzanares R, et al. Impact of canagliflozin in patients with type 2 diabetes after hospitalization for acute heart failure: a cohort study. J Clin Med. 2021;10(3):1–11. https://doi.org/10.3390/JCM10030505 .
doi: 10.3390/JCM10030505
Peiró M, Barrubés J. New context and old challenges in the healthcare system. Rev Esp Cardiol. 2012;65(7):651–5. https://doi.org/10.1016/J.RECESP.2012.02.019 .
doi: 10.1016/J.RECESP.2012.02.019
pubmed: 22633113
Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol. 2023;30(8):634–43. https://doi.org/10.1093/EURJPC/ZWAC315 .
doi: 10.1093/EURJPC/ZWAC315
pubmed: 36582120
Abrahami D, D’Andrea E, Yin H, et al. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. 2023;25(10):2980–8. https://doi.org/10.1111/DOM.15196 .
doi: 10.1111/DOM.15196
pubmed: 37395339
González Manzanares R, Pericet Rodríguez C, Gallo Fernández I, Castillo Domínguez JC, Anguita SM. Heart failure hospitalization during COVID-19 pandemic. SEMERGEN. 2020;46(Suppl 1):91–2. https://doi.org/10.1016/J.SEMERG.2020.06.004 .
doi: 10.1016/J.SEMERG.2020.06.004
pubmed: 32646732
pmcid: 7284259
Frankfurter C, Buchan TA, Kobulnik J, et al. Reduced rate of hospital presentations for heart failure during the COVID-19 pandemic in Toronto. Canada Can J Cardiol. 2020;36(10):1680–4. https://doi.org/10.1016/J.CJCA.2020.07.006 .
doi: 10.1016/J.CJCA.2020.07.006
pubmed: 32682855